Corning, with input from Pfizer and Merck, intends to build a $500 million plant in the U.S. to produce a new pharma glass.

Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.

The FDA actually invited Mitsubishi Tanabe to file Radicava for U.S. approval based on data generated in Japan. Now, it's the first new ALS med in decades.

Two months after snapping up Ariad, Takeda is getting a quick return. The Ariad-developed potential blockbuster Alunbrig won FDA approval Friday.

Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.

Takeda has finished enrolling 20,100 children for a massive phase 3 dengue vaccine study.

A rotavirus vaccine candidate showed better efficacy than Merck’s and GlaxoSmithKline’s approved vaccines in a late-stage trial.

The CDC is preparing a new avian influenza vaccine candidate amid an outbreak in China.